GSK0660 - PPAR Antagonist - 生命科學試劑 - MedChemExpress_第1頁
GSK0660 - PPAR Antagonist - 生命科學試劑 - MedChemExpress_第2頁
GSK0660 - PPAR Antagonist - 生命科學試劑 - MedChemExpress_第3頁
全文預覽已結束

下載本文檔

版權說明:本文檔由用戶提供并上傳,收益歸屬內容提供方,若內容存在侵權,請進行舉報或認領

文檔簡介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEGSK0660Cat. No.: HY-12377CAS No.: 1014691-61-2分式: CHNOS分量: 418.49作靶點: PPAR作通路: Cell Cycle/DNA Damage儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 49 mg/mL (117.09 mM)* means soluble, but

2、saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 2.3895 mL 11.9477 mL 23.8954 mL5 mM 0.4779 mL 2.3895 mL 4.7791 mL10 mM 0.2390 mL 1.1948 mL 2.3895 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備液,并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 GSK0660是有效的 PPAR 和 PPAR 拮抗劑,IC50 均為155 nM。IC50 & Target PPAR/15

3、5 nM (IC50)體外研究GSK0660 is a potent antagonist of PPAR and PPAR, with IC50s of both 155 nM, and is nearly inactive on1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEPPAR and PPAR with IC50s of both 10 M. GSK0660 antagonizes 100% of the activity of PPAR/ witha pIC50 of 6.8. GSK0660 (100 nM) reduces C

4、PT1a (a PPAR/ target gene) expression below the basalvehicle-treated level by approximately 50%, but shows no effect on PDK4 expression, which is also a PPAR/ target gene in skeletal muscle cells 1. GSK0660 (0.5 M) reduces the levels of AMPK and eNOSphosphorylation, and BMP-2, Runx-2 mRNA expression

5、 in MC3T3-E1 cells. GSK0660 (0.1 and 0.5 M)reverses the bezafibrate-induced enchancement of ALP activity on d 7 in MC3T3-E1 cells 2. GSK0660 (1 M) markedly blocks GW501516-mediated attenuation of glutamate release, and the effect of GW501516 onROS generation in BV-2 cells stimulated with LPS. Furthe

6、rmore, GSK0660 significantly reduces inhibitoryeffect of GW501516 on the LPS-induced expression of gp91phox mRNA in BV-2 cells 3.PROTOCOLCell Assay 2 Cell viability is determined by the MTT dye. MC3T3-E1 cells are incubated with bezafibrate (11000 M) for24, 48, or 72 h, and are pretreated with the A

7、MPK inhibitor compound C (5 M), PPAR inhibitor GSK0660(0.5 M), PPAR inhibitor MK886 (10 M), or NOS inhibitor L-NAME (1000 M) followed by bezafibrate (100M) incubation for 48 h. After the incubations, 10 L of MTT is added to each well of a 96-well microplate,and the microplates are placed in an incub

8、ator at 37C for 4 h. One hundred fifty microliters of DMSO isadded to all wells and mixed thoroughly to lyse the cells and dissolve the dark blue crystals. After 10 min, theabsorbance is measured at 570 nm using a microplate reader 2.MCE has not independently confirmed the accuracy of these methods.

9、 They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻 Brain Res Bull. 2018 Jun;140:378-391.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Shearer BG, et al. Identification and characterization of a selective peroxisome proliferator-activated receptor beta/delta (NR1C2)antagonist. Mol Endoc

10、rinol. 2008 Feb;22(2):523-9. Epub 2007 Nov 1.2. Zhong X, et al. Bezafibrate enhances proliferation and differentiation of osteoblastic MC3T3-E1 cells via AMPK and eNOS activation.Acta Pharmacol Sin. 2011 May;32(5):591-600.3. Lee WJ, et al. Activation of PPAR attenuates neurotoxicity by inhibiting lipopolysaccharide-triggered glutamate release in BV-2microglial cells. J Cell Biochem. 2018 Feb 1.McePdfHeightCaution: Product has not been fully

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
  • 4. 未經(jīng)權益所有人同意不得將文件中的內容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內容本身不做任何修改或編輯,并不能對任何下載內容負責。
  • 6. 下載文件中如有侵權或不適當內容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論